FY2024 EPS Estimates for The Cooper Companies, Inc. (NASDAQ:COO) Increased by Analyst

The Cooper Companies, Inc. (NASDAQ:COO) – Equities researchers at Zacks Research boosted their FY2024 earnings per share estimates for Cooper Companies in a research note issued on Wednesday, September 18th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical device company will post earnings of $3.64 per share for the year, up from their prior forecast of $3.55. The consensus estimate for Cooper Companies’ current full-year earnings is $3.66 per share. Zacks Research also issued estimates for Cooper Companies’ Q4 2024 earnings at $0.98 EPS, Q1 2025 earnings at $0.92 EPS, Q3 2025 earnings at $1.04 EPS, Q4 2025 earnings at $1.07 EPS, FY2025 earnings at $3.97 EPS, Q1 2026 earnings at $1.01 EPS, Q2 2026 earnings at $1.05 EPS, Q3 2026 earnings at $1.13 EPS and FY2026 earnings at $4.36 EPS.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.05. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $997.30 million. During the same quarter in the previous year, the company earned $0.84 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year.

COO has been the topic of several other reports. Stifel Nicolaus reiterated a “buy” rating and set a $115.00 price objective (up from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. Wells Fargo & Company upped their price target on Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a research report on Thursday, August 29th. Piper Sandler increased their price objective on Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Morgan Stanley lifted their target price on Cooper Companies from $95.00 to $104.00 and gave the company an “equal weight” rating in a research note on Tuesday, September 10th. Finally, Robert W. Baird increased their price target on shares of Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, August 29th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $115.00.

Cooper Companies Stock Down 0.5 %

COO stock opened at $110.49 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.99 and a quick ratio of 1.18. The firm has a market capitalization of $22.00 billion, a P/E ratio of 64.99, a P/E/G ratio of 2.60 and a beta of 0.98. Cooper Companies has a 52-week low of $75.93 and a 52-week high of $112.38. The company’s 50 day simple moving average is $97.93 and its 200-day simple moving average is $95.54.

Insider Buying and Selling

In other news, COO Daniel G. Mcbride sold 114,992 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the transaction, the chief operating officer now owns 44,696 shares in the company, valued at approximately $4,714,534.08. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CAO Agostino Ricupati sold 1,601 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total value of $172,956.03. Following the completion of the sale, the chief accounting officer now directly owns 4,818 shares in the company, valued at approximately $520,488.54. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Daniel G. Mcbride sold 114,992 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total value of $12,129,356.16. Following the transaction, the chief operating officer now owns 44,696 shares in the company, valued at approximately $4,714,534.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 256,373 shares of company stock worth $27,637,427. Insiders own 2.00% of the company’s stock.

Institutional Trading of Cooper Companies

Institutional investors and hedge funds have recently modified their holdings of the company. Franklin Resources Inc. lifted its position in shares of Cooper Companies by 1.2% during the 4th quarter. Franklin Resources Inc. now owns 3,401 shares of the medical device company’s stock worth $1,287,000 after purchasing an additional 41 shares during the last quarter. LRI Investments LLC boosted its position in shares of Cooper Companies by 4.5% in the second quarter. LRI Investments LLC now owns 2,595 shares of the medical device company’s stock valued at $227,000 after acquiring an additional 112 shares during the period. Commonwealth Equity Services LLC grew its stake in shares of Cooper Companies by 0.8% in the second quarter. Commonwealth Equity Services LLC now owns 15,600 shares of the medical device company’s stock worth $1,362,000 after acquiring an additional 118 shares during the last quarter. First Horizon Advisors Inc. grew its stake in shares of Cooper Companies by 4.8% in the second quarter. First Horizon Advisors Inc. now owns 2,709 shares of the medical device company’s stock worth $236,000 after acquiring an additional 125 shares during the last quarter. Finally, American International Group Inc. increased its position in Cooper Companies by 1.0% during the fourth quarter. American International Group Inc. now owns 13,229 shares of the medical device company’s stock worth $5,006,000 after acquiring an additional 137 shares during the period. 24.39% of the stock is currently owned by institutional investors and hedge funds.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.